8-K: Amylyx Pharmaceuticals to Remove RELYVRIO/ALBRIOZA from Market, Announces Restructuring

Amylyx Pharmaceuticals will discontinue marketing RELYVRIO/ALBRIOZA following disappointing trial results, and implement a major restructuring including a 70% workforce reduction.

Summary

• Amylyx Pharmaceuticals is discontinuing the marketing authorizations for RELYVRIO/ALBRIOZA in the U.S. and Canada based on topline results from the Phase 3 PHOENIX trial.
• The company will remove the product from the market, and it will no longer be available for new patients.
• Current patients in the U.S. and Canada who wish to continue treatment can transition to a free drug program.
• Amylyx is implementing a restructuring plan that includes a reduction of its workforce by approximately 70%.
• The restructuring aims to focus resources on key clinical and preclinical programs and decrease external financial commitments outside of priority areas.
• The company expects to incur approximately $19 million in severance and severance-related charges.
• The restructuring plan is expected to be substantially completed by the end of the third quarter of 2024.
• Amylyx expects to have cash runway into 2026 due to the restructuring.
• The company will continue to evaluate and share learnings from the PHOENIX trial to inform future ALS research.
• Amylyx is advancing AMX0035 in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in ALS.

Sentiment

Score: 3

Explanation: The document conveys a negative sentiment due to the discontinuation of a key product and a significant workforce reduction, despite the company's efforts to focus on other programs and extend its cash runway. The overall tone is one of strategic retreat and adjustment following a major setback.

Positives

• Current patients on RELYVRIO/ALBRIOZA can transition to a free drug program.
• The company is focusing resources on key clinical programs, including AMX0035 in Wolfram syndrome and PSP, and AMX0114 in ALS.
• The restructuring is expected to extend the company's cash runway into 2026.
• Amylyx will continue to collect survival data from the PHOENIX trial and share learnings to inform future ALS research.
• The company is advancing AMX0114, which has shown promise in preclinical studies for ALS.

Negatives

• The company is discontinuing the marketing of RELYVRIO/ALBRIOZA due to disappointing Phase 3 trial results.
• A significant workforce reduction of approximately 70% is being implemented.
• The company expects to incur $19 million in severance costs.
• RELYVRIO/ALBRIOZA will no longer be available for new patients.
• The restructuring may negatively impact the company's internal programs and ability to retain skilled personnel.

Risks

• The restructuring costs and charges may be greater than anticipated or incurred in different periods.
• The restructuring may adversely affect the company's internal programs and ability to recruit and retain skilled personnel.
• The restructuring may negatively impact the company's business operations and reputation.
• The restructuring may not generate the intended benefits as quickly as anticipated.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

Amylyx expects to focus on key clinical milestones, including data readouts from HELIOS (AMX0035 in Wolfram syndrome), ORION (AMX0035 in PSP), and its planned trial of AMX0114 in ALS. The company anticipates a cash runway into 2026.

Management Comments

• Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, stated that the decision to remove RELYVRIO/ALBRIOZA was informed by the PHOENIX trial results, engagement with regulatory authorities, and discussions with the ALS community.
• Camille L. Bedrosian, MD, Chief Medical Officer of Amylyx, highlighted the potential of AMX0035 and AMX0114 in neurodegenerative diseases.
• Cohen and Klee expressed gratitude to the Amylyx team for their contributions and dedication.

Industry Context

The decision to remove RELYVRIO/ALBRIOZA from the market highlights the challenges in developing effective treatments for ALS. The company's focus on other neurodegenerative diseases and new compounds reflects a broader trend in the industry to explore multiple therapeutic avenues.

Comparison to Industry Standards

• The discontinuation of RELYVRIO/ALBRIOZA after a failed Phase 3 trial is not uncommon in the pharmaceutical industry, where clinical trial failures are a regular occurrence.
• The 70% workforce reduction is a significant restructuring, which is a common response to clinical trial setbacks and financial pressures in the biotech sector.
• Companies like Biogen and Ionis Pharmaceuticals have also faced challenges in developing ALS treatments, highlighting the difficulty of this therapeutic area.
• The focus on AMX0035 for Wolfram syndrome and PSP, and AMX0114 for ALS, aligns with the industry trend of exploring multiple targets and mechanisms of action for neurodegenerative diseases.
• The free drug program for current patients is a responsible approach, similar to what other companies have done in similar situations.

Stakeholder Impact

• Shareholders will likely be negatively impacted by the discontinuation of RELYVRIO/ALBRIOZA and the restructuring.
• Employees will be significantly impacted by the 70% workforce reduction.
• Current patients on RELYVRIO/ALBRIOZA will be impacted by the discontinuation of the drug, but can transition to a free drug program.
• The ALS community will be impacted by the removal of RELYVRIO/ALBRIOZA from the market, but the company will continue to share learnings from the PHOENIX trial.
• The company's suppliers and creditors may be impacted by the decrease in external financial commitments.

Next Steps

• Amylyx will present interim data from the Phase 2 HELIOS trial of AMX0035 for Wolfram syndrome on April 10, 2024.
• Topline data from the PHOENIX trial will be presented at the American Academy of Neurology (AAN) Annual Meeting on April 16, 2024.
• The company will continue to evaluate and share learnings from the PHOENIX trial.
• Amylyx plans to initiate a clinical trial studying AMX0114 in ALS in the second half of this year.
• The company will continue to advance AMX0035 in Wolfram syndrome and PSP.
• An interim analysis of the ORION study for AMX0035 in PSP is expected in mid-2025.

Key Dates

Keywords

Amylyx, RELYVRIO, ALBRIOZA, ALS, Restructuring, AMX0035, AMX0114, Wolfram syndrome, PSP, Clinical Trials, Neurodegenerative Diseases, Workforce Reduction